Eyenovia to participate in panel discussion at cantor global healthcare conference

New york, sept. 21, 2023 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), an ophthalmic technology company commercializing mydcombi™ for mydriasis, preparing for regulatory approval of ap13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that michael rowe, ceo, will be participating in a panel discussion at the cantor global healthcare conference, which is taking place september 26-28, 2023, in new york.
EYEN Ratings Summary
EYEN Quant Ranking